$ARX

Accelerant Holdings

No enriched coverage for $ARX in the last 7 days.

No SEC Form 4 filings for $ARX in the last 30 days.

See all $ARX insider activity →
Low

This Dow Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Wednesday

Analysts downgraded several companies: Roth Capital cut SoundThinking (SSTI) to Neutral with a $9 target, Citigroup downgraded Moderna (MRNA) to Sell with an $80 target, TD Cowen downgraded Accelerant (ARX) to Hold with a $20.25 target, Barclays downgraded Mobileye (MBLY) to Equal-Weight with a $9 target, and Citigroup downgraded Dow (DOW) to Neutral with a $30 target.

M&A market trends: BASF/Evonik, arb spreads, and tokenization deals this week

BASF proposed a takeover of Evonik, reflecting defensive consolidation in Europe's chemical sector. Other notable deals include Aquarian's bid for Brighthouse Financial with a 31.4% spread, Thoma Bravo's offer for Accelerant Holdings, and Merck's potential acquisition of Bio-Techne. Bullish's $4.2B deal for Equiniti highlights tokenization trends. Spreads vary, signaling different risk profiles.

ARX sentiment & insider activity

Recent ARX coverage spans financial news, mergers & acquisitions and corporate actions.

What's driving ARX

AlphAI scores every news story that mentions ARX with an AI model for sentiment and relevance, and aggregates insider trades from Accelerant Holdings's SEC EDGAR Form 4 filings. Figures refresh continuously.

News on $ARX

Score
$BAS.DEHighAI 8/10

M&A market trends: BASF/Evonik, arb spreads, and tokenization deals this week

BASF proposed a takeover of Evonik, reflecting defensive consolidation in Europe's chemical sector. Other notable deals include Aquarian's bid for Brighthouse Financial with a 31.4% spread, Thoma Bravo's offer for Accelerant Holdings, and Merck's potential acquisition of Bio-Techne. Bullish's $4.2B deal for Equiniti highlights tokenization trends. Spreads vary, signaling different risk profiles.

Microsoft upgraded, HubSpot initiated: Wall Street's top analyst calls

Stifel upgraded Microsoft (MSFT) to Buy with a $575 price target, citing sustained revenue growth. Susquehanna upgraded RXO Inc. (RXO) to Neutral with a $19 target. JPMorgan upgraded Graphic Packaging (GPK) to Overweight with an $11.50 target. RBC upgraded Lakefront Biotherapeutics (LKFT) to Outperform with a $45 target. Guggenheim upgraded Editas Medicine (EDIT) to Buy with a $5 target. Wedbush downgraded Compass Therapeutics (CMPX) to Neutral with a $1 target.

$ARXLow

ARC, Condor, Cenovus at 52-Week High on News

Multiple Canadian-listed energy and mining stocks hit 52-week highs. ARC Resources reached $33.74; it reported Q2 net income of $353M vs $396.1M a year earlier. Condor Energies rose to $4.22 on a 17,925 boe/d production record. Cenovus hit $44.68 after Q2 results and raised guidance. Other names cited include K2 Gold, MiniLuxe, P2 Gold, ROK Resources, Surge, Tidewater Midstream, Whitecap and Yangarra.

$ARXHighAI 9/10

Why Is Accelerant Going Private Just One Year After Its IPO?

Accelerant Holdings (ARX) agreed to be acquired by Thoma Bravo in an all-cash deal valuing it at over $4 billion, about a year after its July 2025 IPO. ARX shares rose nearly 44% on Aug. 13, 2026. Class A and B holders receive $20.25 per share. Q2 2026 revenue was $356.9 million (+62.9% YoY) and net income $80 million.

$ARXHighAI 9/10

Accelerant Holdings (ARX) Soars 57% as Buyer Bets Big on Firm

Accelerant Holdings (NYSE:ARX) shares rose about 57% after Thoma Bravo agreed to acquire the company for $4 billion. The offer price is $20.25 per share, a 49% premium to the prior close. ARX said shareholders may receive a 6% annual ticking fee if regulatory approvals delay closing, expected in H1.

Related tickers